Experts break down common traits of a "Karent," and how to avoid it in your own parenting.
Former aide returns to the stage – as does "the Downing Street source".
Finally, itch relief that actually works.
Pat Narduzzi thought he had things figured out when the Pittsburgh coach tabbed Vincent Davis as the team's top running back during spring drills. “I sit there and declare a winner in pre-spring ball, and maybe that lit a fire under Izzy.”
We spoke to the actress on why you should nominate a powerhouse woman for L'Oreal's program.
Trying to get a W in your fantasy basketball playoffs matchup? These pickups could help.
ADC Therapeutics SA (NYSE: ADCT) today announced that the U.S. Food and Drug Administration (FDA) has approved ZYNLONTA™ (loncastuximab tesirine-lpyl) for the treatment of adult patients with relapsed or refractory (r/r) large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified (NOS), DLBCL arising from low grade lymphoma and high-grade B-cell lymphoma.1 ZYNLONTA, a CD19-targeted antibody drug conjugate (ADC), has been granted accelerated approval by the FDA based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.
The celebrity doctor being sued by Northern Ireland's first minister over false rumours of an extra-marital affair has told a court he is suffering from "quite serious mental health problems". Lawyers for Arlene Foster commenced defamation proceedings against Dr Christian Jessen after he tweeted unfounded claims the married mother-of-three was engaged in a relationship with a close protection officer. Dr Jessen, who presents the Embarrassing Bodies programme, said he had not read or watched news for 12 months because he was suffering from "really quite serious mental health problems" and knew nothing of the court hearing.
Honest Mark Davis thinks he’s the weakest player mentally on the World Snooker Tour, writes Will Jennings.
FirstEnergy Corp. is cooperating with the U.S. Department of Justice while negotiating a deferred prosecution agreement over its role in secretly funding a $60 million bribery scheme to secure a $1 billion bailout for two Ohio nuclear power plants, company officials said Friday during an earnings call. “We're going to deal with and fully cooperate with the DOJ,” FirstEnergy President and CEO Steven Strah said.
Lucidea, leader in innovative collections management software solutions for archives and provider of ArchivEra, will participate in the Society of California Archivists on April 27th through 30th as a Silver Sponsor.
(Bloomberg) -- Inovio Pharmaceuticals Inc. sank as much as 29% Friday after the U.S. government pulled funding for its Covid-19 vaccine research, a vindication for short sellers who have been amassing positions in the biotech stock.Bears betting against Inovio are set to reap nearly $160 million from Friday’s plunge alone, quintupling their $40 million in profits year-to-date, according to Ihor Dusaniwsky, S3 Partners managing director of predictive analytics.Issues with a key supplier, development delays including a partial hold on testing from the Food and Drug Administration and the abundance of Covid-19 vaccine supplies in the U.S. have hurt the advancement of Plymouth Meeting, Pennsylvania-based Inovio’s shot. Add to that Friday’s news that the Department of Defense will curtail funding for its late-stage vaccine trial because of the broad availability of other shots.“The decision results from the changing environment of Covid-19 with the rapid deployment of vaccines,” the government agency said, according to Inovio’s statement released earlier. “This decision is not a reflection of the awardee or product, rather a fast-moving environment associated with the former Operation Warp Speed on decisions related to future products.”The case of Inovio is among the few recent examples where short sellers betting against a company’s success have paid off. More broadly, hedge funds have elected to side-step placing bearish bets to avoid getting hammered by the rise of Reddit-fueled rallies and euphoric retail investors.Despite backlash from Reddit users earlier this year, Citron Capital’s bets against Inovio were the fund’s largest contributor from shorting to a 155% return in 2020, according to a January letter to investors. Citron was far from being the company’s only skeptic, with roughly a third of shares available for trading sold short as of Friday, data compiled by S3 Partners shows. The total short positions stood at $634 million, the data show.The company will continue to develop its shot through Phase 3 testing, though mostly outside the U.S. “Inovio remains well-positioned to support both pandemic and endemic vaccine needs with INO-4800 and INO-4802,” according to an earlier statement alluding to the company’s Covid-19 shot as well as a vaccine meant to address Covid variants. Inovio declined to comment beyond its initial press release.There are now three vaccines authorized in the U.S. and even with distribution plans for one of those shots currently paused nationally, many health experts say the world’s most lucrative drug market has enough to go around.Sell-side analysts, who are not known for excessive pessimism, were divided on the company’s outlook. Six analysts rate the stock at a hold-equivalent compared to just four who recommended shares to clients while none were sell rated, data compiled by Bloomberg show. Still, the average price target of $15 suggests the shares could more than double from Friday’s level.With the FDA partial pause on the trial unresolved and following Friday’s setback, Inovio’s “window for success, already narrow, closes a bit more,” Piper Sandler analyst Christopher Raymond wrote in a research note. He has a Wall Street low price target of $7.“INO-4800 has not been part of our valuation,” he said, referring to the vaccine candidate. “However, talking with investors, it appears the market has concerned itself with little else. Not a great set-up in our view, and given today’s events, we continue to remain on the sidelines.”(Updates to add analyst ratings, comment from ninth paragraph.)For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2021 Bloomberg L.P.
Of *course* they both have great hair.
Jones stands apart from the other four QBs destined for Round 1 in a big way — he's not a scrambler. Can he succeed in a league that has put so much more emphasis on that?
The International Powder & Bulk Solids (iPBS) Conference & Exhibition to launch Powder Show Connect, a new digital community.
Chad Anderson, Managing Partner of Space Capital, joins Yahoo Finance’s Alexis Christoforous to discuss the latest SpaceX launch, the SPAC boom, and Ark Investment’s position cut in Virgin Galactic.
Graham Norton has criticised the “toxic cabal” of RuPaul’s Drag Race UK fans that have driven some queens off Twitter altogether.
The supermoon is happening in April. How and when to watch it.
The "Star Wars" Luke Skywalker actor didn't spare the hairy details.
Kathy Entwistle, Managing Director at Morgan Stanley, joins Yahoo Finance’s Alexis Christoforous to discuss outlook on the economy and the future of sustainable investing.